Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

35.72 UNCHANGED

Delayed Quote Updated: 11:25 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

September 26, 2023

Gainers Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares jumped 318.5% to $18.54 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi...

Via Benzinga

Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday ↗

September 26, 2023

U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Analyst Expectations for Roivant Sciences's Future ↗

September 18, 2023

Via Benzinga

What 9 Analyst Ratings Have To Say About Roivant Sciences ↗

August 31, 2023

Via Benzinga

8 Analysts Have This to Say About Roivant Sciences ↗

August 15, 2023

Via Benzinga

2 Magnificient Growth Stocks I'm Buying in August ↗

August 02, 2023

These biotech stocks could markedly outperform the broader market.

Via The Motley Fool

Why Is Autoimmune Disease-Focused Immunovant Stock Trading Higher Today? ↗

September 26, 2023

Immunovant Inc (NASDAQ: IMVT), a unit of Roivant Sciences Ltd (NASDAQ: ROIV), announced that subcutaneously administered doses of IMVT-1402 produced dose-dependent reductions in Immunoglobulin G (IgG)...

Via Benzinga

These 2 Biotech Stocks Are Bucking a Down Market Tuesday ↗

September 26, 2023

Stock index futures pointed to a lower open on Wall Street Tuesday morning.

Via The Motley Fool

Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

September 26, 2023

From Roivant Sciences

Via GlobeNewswire

Roivant Announces Completion of Redemption of its Outstanding Warrants

September 11, 2023

From Roivant Sciences

Via GlobeNewswire

Roivant Sciences's Return on Invested Capital Insights ↗

June 29, 2023

Via Benzinga

Roivant Sciences: Is Vivek Ramaswamy’s Biotech Stock A Buy? ↗

September 10, 2023

Roivant Sciences stock price has entered a major bull run as investors remain optimistic about the company’s future. The shares surged to a high of $12.67 on Friday, reaching its highest level since...

Via Talk Markets

Vivek Ramaswamy's Parallels With Warren Buffett Run Deeper Than Wanting To Make Roivant The 'Berkshire Hathaway Of Drug Development' ↗

September 04, 2023

Presidential hopeful Vivek Ramaswamy and Warren Buffett may share different political ideologies but they have at least a couple of things in common.

Via Benzinga

2 Supercharged Growth Stocks Billionaires Can't Stop Buying ↗

August 28, 2023

A top hedge fund has been steadily buying these two growth stocks in 2023.

Via The Motley Fool

If You Invested $1000 In Vivek Ramaswamy-Founded Roivant When He Declared Presidential Bid, Here's How Much You'd Have Now ↗

August 25, 2023

Roivant stock has outperformed the broader market and the biotech sector this year, mirroring the rise in the fortunes of its founder Vivek Ramaswamy.

Via Benzinga

Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants

August 17, 2023

From Roivant Sciences

Via GlobeNewswire

Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales ↗

August 14, 2023

The company is working on a treatment for stomach diseases ulcerative colitis and Crohn's disease.

Via Investor's Business Daily

Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update

August 14, 2023

From Roivant Sciences

Via GlobeNewswire

3 Biotech Stocks That Analysts Are Drooling Over ↗

August 07, 2023

With the medical science realm representing one of the most complex markets, these top analyst biotech picks can be worth your time.

Via InvestorPlace

Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023

August 03, 2023

From Roivant Sciences

Via GlobeNewswire

Earnings Scheduled For August 14, 2023 ↗

August 14, 2023

Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million.

Via Benzinga

Roivant Announces Redemption of Outstanding Warrants

August 02, 2023

From Roivant Sciences

Via GlobeNewswire

Vivek 'Da Vek' Ramaswamy: The 2024 Presidential Candidate Who Might Just Rap His Inauguration Speech ↗

July 28, 2023

Donald Trump and Ron DeSantis have been the runaway favorites for the GOP nomination in the 2024 election, but there’s one candidate that has been climbing up the polls and gaining support from...

Via Benzinga

Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease

July 27, 2023

From Roivant Sciences

Via GlobeNewswire

3 Biotech Stocks for Getting Rich in 2023 ↗

July 18, 2023

These 3 biotech stocks have seen stable or growing revenue this year. This makes them companies to keep on your watchlist.

Via InvestorPlace

2 Nasdaq Stocks That Could Soar This Week ↗

July 16, 2023

BridgeBio Pharma and Roivant Sciences could make big moves this week.

Via The Motley Fool

Hollywood Wants To Use AI Replicas Of Actors, Major US Banks Deliver Q2 Earnings, Artificial Sweetener Aspartame Classified As 'Possible Carcinogen:' Today's Top Stories ↗

July 14, 2023

Benzinga

Via Benzinga

Roivant Surges As Roche Reportedly Considers $7 Billion Drug Takeover ↗

July 14, 2023

The report sent Roivant Sciences higher Friday, but a deal is far from guaranteed.

Via Investor's Business Daily

Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal ↗

July 14, 2023

Roivant Sciences Ltd (NASDAQ: ROIV), a biotech company founded by Vivek Ramaswamy, a Republican presidential candidate, is reportedly in discussions with Roche Holdings AG (OTC: RHHBY)

Via Benzinga

Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program

July 11, 2023

Joining Adobe, Spotify, Nvidia, Morgan Stanley, and many others

From Roivant Sciences

Via GlobeNewswire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.